NASDAQ:PYXS Pyxis Oncology Q1 2026 Earnings Results & Report $1.44 +0.03 (+2.13%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.53%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pyxis Oncology missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.37 versus the -$0.35 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Pyxis Oncology EPS ResultsActual EPS-$0.37Consensus EPS -$0.35Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersPyxis Oncology Revenue ResultsActual RevenueN/AExpected Revenue$19 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pyxis Oncology Q1 2026 Earnings FAQ Did Pyxis Oncology beat earnings estimates for Q1 2026? Pyxis Oncology (NASDAQ:PYXS) reported earnings of -$0.37 per share for Q1 2026, missing the consensus estimate of -$0.35. The report was announced on Thursday, May 14, 2026. Pyxis Oncology Earnings HeadlinesPyxis Oncology (NASDAQ:PYXS) Upgraded at Wall Street ZenNovember 10, 2026 | americanbankingnews.comPyxis Oncology (NASDAQ:PYXS) Stock Gets Price Target Trim from WedbushNovember 9, 2026 | americanbankingnews.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 18 at 1:00 AM | Porter & Company (Ad)Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $7.00November 9, 2026 | americanbankingnews.comPyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)November 5, 2026 | globenewswire.comPyxis Oncology to Participate in Upcoming Investor ConferencesOctober 28, 2026 | globenewswire.comSee More Pyxis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email. Email Address About Pyxis OncologyPyxis Oncology (NASDAQ:PYXS) is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets. Founded in 2019 and based in Boston, Massachusetts, Pyxis Oncology was co-founded by Lara Sullivan, who has served as its president and chief executive officer. The company is focused on developing its therapies and does not have marketed products.View Pyxis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.